Provided by Tiger Trade Technology Pte. Ltd.

Erasca, Inc.

17.63
+0.55003.22%
Post-market: 17.640.0100+0.06%19:48 EDT
Volume:2.45M
Turnover:43.10M
Market Cap:6.17B
PE:-18.16
High:17.84
Open:17.28
Low:17.21
Close:17.08
52wk High:24.28
52wk Low:1.33
Shares:349.76M
Float Shares:291.15M
Volume Ratio:0.97
T/O Rate:0.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9710
EPS(LYR):-0.4393
ROE:-78.25%
ROA:-21.39%
PB:17.04
PE(LYR):-40.14

Loading ...

Erasca, Inc. : H.c. Wainwright Raises Target Price to $20 From $15

THOMSON REUTERS
·
Mar 13

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 13

U.S. RESEARCH ROUNDUP-Adobe, KLA, Ulta Beauty

Reuters
·
Mar 13

Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results

GlobeNewswire
·
Mar 13

Erasca: Pan-RAS Data Momentum and Strategic Partnerships Underpin Upsized Revenue Outlook and Buy Rating

TIPRANKS
·
Mar 11

Erasca price target raised to $20 from $10 at Stifel

TIPRANKS
·
Mar 11

Erasca Exercises Option to Extend Cancer Drug Candidate License to Gain Global Rights

MT Newswires Live
·
Mar 10

Erasca Inc - Initial Phase 1 Monotherapy Data for Eras-0015 Expected in H1 2026

THOMSON REUTERS
·
Mar 10

Erasca Inc - Exercises Option to Secure Worldwide Rights for Eras-0015

THOMSON REUTERS
·
Mar 10

Erasca expands ERAS-0015 license to secure worldwide rights including China, Hong Kong and Macau

Reuters
·
Mar 10

Erasca Chief Medical Officer Morris Shannon Disposes of Common Shares

Reuters
·
Mar 06

Erasca Is Maintained at Buy by Clear Street

Dow Jones
·
Mar 06

Erasca price target raised to $20 from $11 at Clear Street

TIPRANKS
·
Mar 06

These stocks are set for high-stakes earnings moves. Here's your trading playbook.

Dow Jones
·
Mar 06

Erasca, Tango Therapeutics Partner on Phase 1/2 Trial for Combination Cancer Therapy

MT Newswires Live
·
Mar 05

Tango Therapeutics Q4 net loss widens

Reuters
·
Mar 05

BRIEF-Erasca And Tango Therapeutics Enter Into Clinical Collaboration To Evaluate Combination Of ERAS-0015 And Vopimetostat

Reuters
·
Mar 05

Tango Therapeutics posts FY 2025 collaboration revenue of USD 62.4 million +108.2%

Reuters
·
Mar 05

Erasca Inc: Co Will Supply Eras-0015 Free of Charge, and Tango Will Be Trial Sponsor

THOMSON REUTERS
·
Mar 05

Erasca Inc: Each Company Will Retain Commercial Rights to Their Respective Compound

THOMSON REUTERS
·
Mar 05